Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

#AAD26: Tanabe’s Phase 3 win for drug targeting rare diseases that cause pain upon light exposure

Published

on

Tanabe Pharma unveiled positive data from a Phase 3 trial of its oral drug for a pair of rare diseases, its first major clinical milestone after it was acquired by Bain Capital …

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Vertex’s biggest overhang: a rival 50 times smaller

Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics “looms large” over Vertex.

Read More

Published

on

Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics “looms large” over Vertex.

Read More

Continue Reading

Uncategorized

Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss

Published

on

The anti-TL1A antibody from Merck’s 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside second-quarter earnings.

Continue Reading

Uncategorized

BioNTech cuts sales forecast on slumping demand for COVID-19 vaccine

Published

on

Lower vaccine demand across every market and more acute pressures in Germany led BioNTech to lower the midpoint of its sales outlook by almost 20%.

Continue Reading
Advertisement

Trending